{"created":"2023-05-15T16:49:26.850246+00:00","id":26907,"links":{},"metadata":{"_buckets":{"deposit":"5483fe60-9f96-41b5-9bf7-88ec1db2789f"},"_deposit":{"created_by":6,"id":"26907","owners":[6],"pid":{"revision_id":0,"type":"depid","value":"26907"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00026907","sets":["8:9"]},"author_link":["119647","119653","119654","119646","119652","119655","119657","119658","119650","119643","119660","119645","119642","119641","119649","119644","119651","119659","119656","119648"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-09-17","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"18","bibliographicPageStart":"4221","bibliographicVolumeNumber":"10","bibliographic_titles":[{"bibliographic_title":"Journal of Clinical Medicine"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-agent amrubicin chemotherapy for thoracic malignancies. Patients and methods: The medical records of consecutive patients with thoracic malignancies, including SCLC and non-small cell lung cancer (NSCLC), who were treated with single-agent amrubicin chemotherapy in cycle 1 between January 2010 and March 2020, were retrospectively analyzed. Results: One hundred and fifty-six patients from four institutions were enrolled. Their characteristics were as follows: median age (range): 68 (32–86); male/female: 126/30; performance status (0/1/2): 9/108/39; SCLC/NSCLC/others: 111/30/15; and prior treatment (0/1/2/3-): 1/96/31/28. One hundred and thirty-four (86%) and 97 (62%) patients experienced grade 3/4 and grade 4 neutropenia, respectively. One hundred and twelve patients (72%) required therapeutic G-CSF treatment, and 47 (30%) developed FN. Prophylactic PEG-G-CSF was not used in cycle 1 in any case. The median overall survival of the patients with FN was significantly shorter than that of the patients without FN (7.2 vs. 10.0 months, p = 0.025). Conclusions: The real-world incidence rate of FN among patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy was 30%. It is suggested that prophylactic G-CSF should be administered during the practical use of single-agent amrubicin chemotherapy for patients who have already received chemotherapy. ","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Journal of Clinical Medicine, 10(18), art. no. 4221; 2021","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"MDPI"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.3390/jcm10184221","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"2077-0383","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Dotsu, Yosuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamaguchi, Hiroyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fukuda, Minoru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Suyama, Takayuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Honda, Noritaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Umeyama, Yasuhiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Taniguchi, Hirokazu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Gyotoku, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takemoto, Shinnosuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tagawa, Ryuta"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ogata, Ryosuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tomono, Hiromi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shimada, Midori"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Senju, Hiroaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakatomi, Katsumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nagashima, Seiji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Soda, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ikeda, Hiroaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ashizawa, Kazuto"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Mukae, Hiroshi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-12-02"}],"displaytype":"detail","filename":"JCM10_4221.pdf","filesize":[{"value":"1.6 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"JCM10_4221.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/26907/files/JCM10_4221.pdf"},"version_id":"a790027f-3dfe-4824-b1aa-f6b49f3c8f4f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"amrubicin","subitem_subject_scheme":"Other"},{"subitem_subject":"chemotherapy","subitem_subject_scheme":"Other"},{"subitem_subject":"granulocyte colony-stimulating factor","subitem_subject_scheme":"Other"},{"subitem_subject":"febrile neutropenia","subitem_subject_scheme":"Other"},{"subitem_subject":"lung cancer","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor"}]},"item_type_id":"2","owner":"6","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-12-02"},"publish_date":"2021-12-02","publish_status":"0","recid":"26907","relation_version_is_last":true,"title":["Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor"],"weko_creator_id":"6","weko_shared_id":-1},"updated":"2023-05-15T20:06:54.947240+00:00"}